Eva-Maria Thurner1, Sabine Krenn-Pilko1, Uwe Langsenlehner2, Tatjana Stojakovic3, Martin Pichler4, Armin Gerger4, Karin S Kapp1, Tanja Langsenlehner5. 1. Department of Therapeutic Radiology and Oncology, Comprehensive Cancer Center Graz, Medical University of Graz, Auenbruggerplatz 32, 8036, Graz, Austria. 2. Division of Internal Medicine, Outpatient Department Graz, Graz, Austria. 3. Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria. 4. Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Graz, Austria. 5. Department of Therapeutic Radiology and Oncology, Comprehensive Cancer Center Graz, Medical University of Graz, Auenbruggerplatz 32, 8036, Graz, Austria. tanja.langsenlehner@medunigraz.at.
Abstract
PURPOSE: Fibrinogen plays an important role in the pathophysiology of tumour cell invasion and metastases. In recent studies, an elevated plasma fibrinogen level has been associated with poor prognosis in different types of cancer. The present study was performed to analyse the prognostic impact of an elevated fibrinogen level in prostate cancer patients. METHODS: We evaluated data from 268 prostate cancer patients who underwent 3D conformal radiotherapy between 1999 and 2006 at a single tertiary academic center. Cancer-specific survival (CSS), overall survival (OS), and clinical disease-free survival (DFS) were assessed using the Kaplan-Meier method. Univariable and multivariable Cox regression models were performed for each endpoint. RESULTS: Applying receiver operating characteristics (ROC) curve analysis, the optimal cut-off level for the plasma fibrinogen level was 530 mg dl(-1), respectively. Univariable (HR 3.638, 95 % CI 1.15-11.47, p = 0.027) and multivariable analyses (HR 3.964, 95 % CI 1.06-14.87, p = 0.041) revealed a significant correlation between increased plasma fibrinogen and CSS. Univariable analysis also showed a significant association between the elevated plasma fibrinogen level and decreased OS (HR 3.242, 95 % CI 1.53-6.89, p = 0.002), that remained significant in multivariable analysis (HR 3.215, 95 % CI 1.44-7.19, p = 0.004). No significant associations were found for clinical DFS. CONCLUSION: Although our data show a significant association between an elevated plasma fibrinogen level and poor prostate cancer prognosis, they have to be interpreted cautiously. Limitations of the present study are caused by its retrospective design, the limited accuracy obtained using ROC curve analysis, and potential confounding factors like cardiovascular disease and inflammatory diseases that have not been accounted for.
PURPOSE:Fibrinogen plays an important role in the pathophysiology of tumour cell invasion and metastases. In recent studies, an elevated plasma fibrinogen level has been associated with poor prognosis in different types of cancer. The present study was performed to analyse the prognostic impact of an elevated fibrinogen level in prostate cancerpatients. METHODS: We evaluated data from 268 prostate cancerpatients who underwent 3D conformal radiotherapy between 1999 and 2006 at a single tertiary academic center. Cancer-specific survival (CSS), overall survival (OS), and clinical disease-free survival (DFS) were assessed using the Kaplan-Meier method. Univariable and multivariable Cox regression models were performed for each endpoint. RESULTS: Applying receiver operating characteristics (ROC) curve analysis, the optimal cut-off level for the plasma fibrinogen level was 530 mg dl(-1), respectively. Univariable (HR 3.638, 95 % CI 1.15-11.47, p = 0.027) and multivariable analyses (HR 3.964, 95 % CI 1.06-14.87, p = 0.041) revealed a significant correlation between increased plasma fibrinogen and CSS. Univariable analysis also showed a significant association between the elevated plasma fibrinogen level and decreased OS (HR 3.242, 95 % CI 1.53-6.89, p = 0.002), that remained significant in multivariable analysis (HR 3.215, 95 % CI 1.44-7.19, p = 0.004). No significant associations were found for clinical DFS. CONCLUSION: Although our data show a significant association between an elevated plasma fibrinogen level and poor prostate cancer prognosis, they have to be interpreted cautiously. Limitations of the present study are caused by its retrospective design, the limited accuracy obtained using ROC curve analysis, and potential confounding factors like cardiovascular disease and inflammatory diseases that have not been accounted for.
Authors: Kris A Steinbrecher; Netanel A Horowitz; Elizabeth A Blevins; Kelley A Barney; Maureen A Shaw; Eleana Harmel-Laws; Fred D Finkelman; Matthew J Flick; Malinda D Pinkerton; Kathryn E Talmage; Keith W Kombrinck; David P Witte; Joseph S Palumbo Journal: Cancer Res Date: 2010-03-16 Impact factor: 12.701
Authors: V Tiedje; D Dunkler; C Ay; B Horvath; P Quehenberger; M Pabinger; C Zielinski; I Pabinger; C Mannhalter Journal: Thromb Haemost Date: 2011-09-08 Impact factor: 5.249
Authors: V Seebacher; S Polterauer; C Grimm; H Husslein; H Leipold; K Hefler-Frischmuth; C Tempfer; A Reinthaller; L Hefler Journal: Br J Cancer Date: 2010-02-16 Impact factor: 7.640
Authors: Stephan Polterauer; Veronika Seebacher; Katrin Hefler-Frischmuth; Christoph Grimm; Georg Heinze; Clemens Tempfer; Alexander Reinthaller; Lukas Hefler Journal: Am J Obstet Gynecol Date: 2009-06 Impact factor: 8.661
Authors: Y Wang; W Yin; Z Wang; J Huang; J Pan; Y Zhu; F Xu; X Shao; J Sha; Y Cai; Q Liu; B Dong; W Xue; Y Huang Journal: Prostate Cancer Prostatic Dis Date: 2016-03-08 Impact factor: 5.554
Authors: Peng Ding; Chen Zheng; Guohui Cao; Ziming Gao; Yuying Lei; Peng Deng; Bin Hou; Kai Li Journal: Cancer Med Date: 2019-05-02 Impact factor: 4.452